Principal Scientist
Full-time
London, UK
Senior / Principal Scientist, Antibody Characterisation
Location: White City, London
Permanent | Full-time | Competitive Salary + Benefits
Join a $115M-funded biotech pioneering the next generation of antibody therapeutics.
Northreach is partnering with RQ Biotechnology, an ambitious UK biotech that recently secured $115 million (£85.5 million) in Series A funding, backed by leading global life sciences investors including Frazier Life Sciences, EQT Life Sciences, Forbion and LifeArc Ventures.
RQ Bio is developing an innovative platform of long-acting monoclonal antibodies, designed to provide broad, durable protection against influenza, particularly for vulnerable patients who may not respond adequately to conventional vaccines.
Its lead programme, RQB01, is advancing towards clinical development, while the company continues to expand its next-generation antibody discovery pipeline.
With significant investment, experienced scientific leadership and ambitious growth plans, this is an exciting opportunity to join a biotech at a pivotal stage of development.
The Opportunity
We are seeking a Senior / Principal Scientist, Antibody Characterisation to take scientific ownership of key characterisation capabilities and help shape the future of RQ Bio's antibody pipeline.
You will combine hands-on laboratory science with scientific leadership, working in a collaborative, fast-moving biotech environment where your expertise directly influences therapeutic development.
Key responsibilities:
- Lead antibody characterisation using SPR/BLI, ELISA and complementary biophysical techniques.
- Develop and optimise assays assessing antibody binding, kinetics, stability and developability.
- Drive antibody lead optimisation and candidate selection.
- Characterise next-generation formats, including bispecifics, multispecifics and ADCs.
- Lead scientific workstreams, mentor scientists and oversee external CRO activities.
About You
- PhD in Biochemistry, Biophysics, Protein Science or a related field, or equivalent experience.
- Proven therapeutic antibody R&D experience within biotech or pharma.
- Strong, recent hands-on SPR/BLI and antibody characterisation expertise.
- Experience in antibody optimisation, developability and candidate selection.
- Exposure to advanced antibody formats.
- Ability to take technical ownership and work collaboratively across multidisciplinary R&D teams.
Why RQ Bio?
- $115M Series A funding supporting clinical development and pipeline expansion.
- Differentiated antibody discovery technology targeting conserved regions of influenza viruses.
- Real scientific ownership, with the autonomy to build capabilities and influence candidate progression.
- Experienced scientific leadership and the opportunity to collaborate closely with leading antibody and virology researchers.
- Career development, with flexibility to appoint at Senior or Principal Scientist level.
- Purpose-driven science, developing innovative medicines for patients who remain vulnerable despite vaccination.